COMPARATIVE STUDY OF CHLOROFORM FRACTION OF RUBIA CORDIFOLIA AND CARVEDILOL AGAINST IN VIVO MODEL OF MYOCARDIAL ISCHEMIAREPERFUSION INJURY IN RATS

Shabari Girinath K*1, D. Midhun Kumar2, Lohithasu Duppala2, Pankaj Bhatt3

Present study evaluated the cardioprotective effect of chloroform fraction of root of Rubiacordifolia (CFRRC) against ischemia-reperfusion (I-R) and Cardioprotective effect of CFRRC was evaluated. The antioxidant and free radical scavenging activity of CFRRC was supported by its in vitro DPPH scavenging activity. Serum estimations revealed a significant decrease in activities of cardiac biomarkers (LDH and CK-MB) in the groups pre-treated with CFRRC. Pre-treatment with CFRRC prevented GSH depletion and also inhibited lipid peroxidation in heart tissue. in vitro and in vivo studies of CFRRC and comparative study with Carvedilol indicate that pretreatment with CFRRC at the doses (100 and 200 mg/kg, i.p.) showed significant therapeutically changes in a dose dependent manner against myocardial ischemia-reperfusion injury. Further clinical research is needed to confirm the beneficial effects of Rubiacordifolia in various cardiovascular disorders.